Insider Buying: AngioDynamics, Inc. (NASDAQ:ANGO) CEO Purchases 20,000 Shares of Stock

AngioDynamics, Inc. (NASDAQ:ANGO) CEO James C. Clemmer bought 20,000 shares of the company’s stock in a transaction that occurred on Monday, October 7th. The stock was bought at an average price of $6.03 per share, for a total transaction of $120,600.00. Following the acquisition, the chief executive officer now directly owns 681,582 shares of the company’s stock, valued at $4,109,939.46. The trade was a 0.00 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

AngioDynamics Price Performance

Shares of AngioDynamics stock opened at $6.08 on Thursday. The company’s fifty day simple moving average is $7.41 and its 200-day simple moving average is $6.65. The stock has a market capitalization of $243.53 million, a PE ratio of -1.26 and a beta of 0.65. AngioDynamics, Inc. has a 1-year low of $5.26 and a 1-year high of $8.25.

AngioDynamics (NASDAQ:ANGO) last announced its quarterly earnings data on Thursday, October 3rd. The medical instruments supplier reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.04. The firm had revenue of $67.50 million for the quarter, compared to the consensus estimate of $67.93 million. AngioDynamics had a negative net margin of 61.55% and a negative return on equity of 4.91%. The company’s revenue was down 14.2% on a year-over-year basis. During the same period last year, the firm earned ($0.12) EPS. As a group, research analysts anticipate that AngioDynamics, Inc. will post -0.41 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on ANGO shares. Canaccord Genuity Group dropped their price target on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, October 4th. HC Wainwright reiterated a “buy” rating and set a $14.00 price target on shares of AngioDynamics in a research note on Friday, October 4th.

Institutional Trading of AngioDynamics

Several institutional investors and hedge funds have recently modified their holdings of ANGO. Millennium Management LLC raised its position in shares of AngioDynamics by 41.9% during the 2nd quarter. Millennium Management LLC now owns 1,793,454 shares of the medical instruments supplier’s stock valued at $10,850,000 after purchasing an additional 529,861 shares during the period. Fund 1 Investments LLC bought a new stake in shares of AngioDynamics during the 4th quarter valued at $3,896,000. Western Standard LLC raised its position in shares of AngioDynamics by 878.5% during the 1st quarter. Western Standard LLC now owns 523,393 shares of the medical instruments supplier’s stock valued at $3,072,000 after purchasing an additional 469,906 shares during the period. First Eagle Investment Management LLC bought a new stake in AngioDynamics in the 2nd quarter valued at $1,321,000. Finally, Systematic Financial Management LP increased its holdings in AngioDynamics by 8.4% in the 2nd quarter. Systematic Financial Management LP now owns 2,109,561 shares of the medical instruments supplier’s stock valued at $12,763,000 after acquiring an additional 162,972 shares during the last quarter. 89.43% of the stock is currently owned by institutional investors.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.